Five-year antimicrobial susceptibility trends among bacterial isolates from a tertiary health-care facility in Kigali, Rwanda

American Journal of Tropical Medicine and Hygiene

Volumn 95, Issue 6, 2016, Pages 1277-1283

  Carroll, Makeda ^a   Rangaiahagari, Ashok ^b,c   Musabeyezu, Emmanuel ^c   Singer, Donald ^d   Ogbuagu, Onyema ^e  

^a Department of Public Health ^*  (United States)

^b SMBT Institute of Medical Sciences and Research Centre   (India)

^c KING FAISAL HOSPITAL   (Rwanda)

^d Fellowship of Postgraduate Medicine   (United Kingdom)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFALEXIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS; ESCHERICHIA COLI; KLEBSIELLA; NONHUMAN; PENICILLIN RESISTANCE; PSEUDOMONAS; RWANDA; STAPHYLOCOCCUS AUREUS; TERTIARY CARE CENTER; BACTERIAL INFECTIONS; HUMAN; INFECTION CONTROL; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; INFECTION CONTROL; RWANDA; TERTIARY CARE CENTERS;

EID: 85005952398     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.16-0392     Document Type: Article

References (31)

1. Levy SB, 2002. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 49: 25-30.
2. Gelband H, Laxminarayan R, 2015. Tackling antimicrobial resistance at global and local scales. Trends Microbiol 23: 524-526.
3. Lusti-Narasimhan M, Pessoa-Silva CL, Temmerman M, 2013. Moving forward in tackling antimicrobial resistance: WHO actions. Sex Transm Infect 89 (Suppl 4): iv57-iv59.
4. Tapsall JW, Ndowa F, Lewis DA, Unemo M, 2009. Meeting the public health challenge of multidrug-and extensively drugresistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 7: 821-834.
5. Shallcross LJ, Davies SC, 2014. The World Health Assembly resolution on antimicrobial resistance. J Antimicrob Chemother 69: 2883-2885.
6. Shears P, 2001. Antibiotic resistance in the tropics. Epidemiology and surveillance of antimicrobial resistance in the tropics. Trans R Soc Trop Med Hyg 95: 127-130.
7. Omulo S, Thumbi SM, Njenga MK, Call DR, 2015. A review of 40 years of enteric antimicrobial resistance research in eastern Africa: what can be done better? Antimicrob Resist Infect Control 4: 1.
8. Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA, 2007. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis 13: 1640-1646.
9. Perovic O, Singh-Moodley A, Duse A, Bamford C, Elliott G, Swe-Han KS, Kularatne R, Lowman W, Whitelaw A, Nana T, Wadula J, Lekalakala R, Saif A, Fortuin De-Smit M, Marais E, 2014. National sentinel site surveillance for antimicrobial resistance in Klebsiella pneumoniae isolates in South Africa, 2010-2012. S Afr Med J 104: 563-568.
10. Bogaerts J, Verhaegen J, Munyabikali JP, Mukantabana B, Lemmens P, Vandeven J, Vandepitte J, 1997. Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing frequency of multiple resistance. Diagn Microbiol Infect Dis 28: 165-171.
11. Bogaerts J, Lepage P, Taelman H, Rouvroy D, Batungwanayo J, Kestelyn P, Hitimana DG, Van de Perre P, Vandepitte J, Verbist L, Verhaegen J, 1993. Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from Rwanda, 1984-1990. J Infect 27: 157-168.
12. Van Dyck E, Karita E, Abdellati S, Dirk VH, Ngabonziza M, Lafort Y, Laga M, 2001. Antimicrobial susceptibilities of Neisseria gonorrhoeae in Kigali, Rwanda, and trends of resistance between 1986 and 2000. Sex Transm Dis 28: 539-545.
13. Bogaerts J, Van Dyck E, Mukantabana B, Munyabikali JP, Martinez Tello W, 1998. Auxotypes, serovars, and trends of antimicrobial resistance of Neisseria gonorrhoeae in Kigali, Rwanda (1985-93). Sex Transm Infect 74: 205-209.
14. Lepage P, Bogaerts J, Van Goethem C, Hitimana DG, Nsengumuremyi F, 1990. Multiresistant Salmonella typhimurium systemic infection in Rwanda. Clinical features and treatment with cefotaxime. J Antimicrob Chemother 26 (Suppl A): 53-57.
15. Muvunyi CM, Masaisa F, Bayingana C, Mutesa L, Musemakweri A, Muhirwa G, Claeys GW, 2011. Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines. Am J Trop Med Hyg 84: 923-928.
16. Ntirenganya C, Manzi O, Muvunyi CM, Ogbuagu O, 2015. High prevalence of antimicrobial resistance among common bacterial isolates in a tertiary healthcare facility in Rwanda. Am J Trop Med Hyg 92: 865-870.
17. Kimang'a A, 2012. A situational analysis of antimicrobial drug resistance in Africa: are we losing the battle? Ethiop J Health Sci 22: 135-143.
18. Center for Disease Dynamics, Economics, and Policy, 2011. Situation Analysis: Antibiotic Use and Resistance in South Africa. Global Antibiotic Resistance Partnership, 549-596.
19. Kouegnigan Rerambiah L, Ndong JC, Mbakob Mengue Massoua P, Medzegue S, Elisee-Ndam M, Mintsa-Ndong A, Djoba Siawaya JF, 2014. Antimicrobial profiles of bacterial clinical isolates from the Gabonese National Laboratory of Public Health: data from routine activity. Int J Infect Dis 29: 48-53.
20. Sekyere JO, Govinden U, Essack S, 2015. The molecular epidemiology and genetic environment of carbapenemases detected in Africa. Microb Drug Resist 22: 59-68.
21. Manenzhe RI, Zar HJ, Nicol MP, Kaba M, 2015. The spread of carbapenemase-producing bacteria in Africa: a systematic review. J Antimicrob Chemother 70: 23-40.
22. Mushi MF, Mshana SE, Imirzalioglu C, Bwanga F, 2014. Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania. BioMed Res Int 2014: 303104.
23. Mathers AJ, Peirano G, Pitout JD, 2015. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev 28: 565-591.
24. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV, 2013. The epidemic of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio 4: e00377-13.
25. Omuse G, Kabera B, Revathi G, 2014. Low prevalence of methicillin resistant Staphylococcus aureus as determined by an automated identification system in two private hospitals in Nairobi, Kenya: a cross sectional study. BMC Infect Dis 14: 669.
26. Predari SC, Gutierrez MA, Ribas C, Molinari GS, Santoianni JE, 1991. Susceptibility of Enterococcus faecalis to twelve antibiotics, time-kill assays, and high-level aminoglycoside resistance in a university hospital in Argentina. Rev Argent Microbiol 23: 67-78.
27. Weinstein MP, 2001. Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol 39: 2729-2731.
28. Conceicao N, da Silva LE, Darini AL, Pitondo-Silva A, de Oliveira AG, 2014. Penicillin-resistant, ampicillin-susceptible Enterococcus faecalis of hospital origin: pbp4 gene polymorphism and genetic diversity. Infect Genet Evol 28: 289-295.
29. Kimang'a AN, 2012. A situational analysis of antimicrobial drug resistance in Africa: are we losing the battle? Ethiop J Health Sci 22: 135-143.
30. Whitelaw AC, 2015. Role of infection control in combating antibiotic resistance. S Afr Med J 105: 421.
31. Ramsamy Y, Muckart DJ, Han KS, 2013. Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy. S Afr Med J 103: 371-376.